Adma Biologics Inc. (ADMA)
NASDAQ (NMS) NASDAQ (NMS) Primary 
Pharma Stock Poised to Bounce Off Support
Pharmaceutical concern ADMA Biologics Inc (NASDAQ:ADMA) has been consolidating above familiar pressure at the $16 region since mid-January.
ADMA Loses 8.9% in a Month: How Should You Play the Stock?
ADMA Biologics' shares lose 8.9% in a month after putting up a phenomenal performance in the past 12 months. While the prospects remain sound, the exceptional rally witnessed by the stock might limit any further gain.
Adma Biologics (ADMA) Advances But Underperforms Market: Key Facts
In the closing of the recent trading day, Adma Biologics (ADMA) stood at $16.92, denoting a +0.3% change from the preceding trading day.
ADMA Biologics: Recent Pullback Is A Perfect Opportunity To Add
ADMA Biologics specializes in primary immune deficiencies with Asceniv, a high-margin, unique product that outperforms competitors and has significant growth potential in the U.S. market. Asceniv's high-titer plasma offers superior protection with minimal side effects, positioning it as a leading second-line treatment for severe PI patients. ADMA's strategic plasma collection expansion and patented methods ensure a reliable supply, supporting future growth and high-margin revenue projections exceeding $1 billion by 2030.
Adma Biologics (ADMA) Ascends While Market Falls: Some Facts to Note
Adma Biologics (ADMA) concluded the recent trading session at $16.47, signifying a +1.98% move from its prior day's close.
Adma Biologics (ADMA) Stock Declines While Market Improves: Some Information for Investors
Adma Biologics (ADMA) closed the most recent trading day at $16.17, moving -0.12% from the previous trading session.
Adma Biologics (ADMA) Rises Higher Than Market: Key Facts
Adma Biologics (ADMA) concluded the recent trading session at $16.47, signifying a +1.92% move from its prior day's close.
There May Still Be Time to Get in on These 3 Trending Biotechs
Despite the strength of the economy overall, 2024 was a challenging year for the biotech industry. The high cost of borrowing—particularly prior to the Fed's first rate cut in several years in September—coupled with a shifting landscape for the healthcare sector dampened prospects for many firms.
Adma Biologics (ADMA) Stock Sinks As Market Gains: Here's Why
The latest trading day saw Adma Biologics (ADMA) settling at $16.32, representing a -1.03% change from its previous close.
ADMA Stock Catapults 275.7% in a Year: How Should You Play the Stock?
ADMA Biologics performance in the past twelve months has been phenomenal. While the prospects remain sound, the exceptional rally witnessed by the stock might limit any further gain.
Adma Biologics (ADMA) Surpasses Market Returns: Some Facts Worth Knowing
Adma Biologics (ADMA) closed at $18.56 in the latest trading session, marking a +1.48% move from the prior day.
Is It Worth Investing in Adma Biologics (ADMA) Based on Wall Street's Bullish Views?
When deciding whether to buy, sell, or hold a stock, investors often rely on analyst recommendations. Media reports about rating changes by these brokerage-firm-employed (or sell-side) analysts often influence a stock's price, but are they really important?
